# A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants

> **NCT02440035** · PHASE1 · COMPLETED · sponsor: **Crucell Holland BV** · enrollment: 48 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **BIOLOGICAL:** Ad35.RSV.FA2
- **BIOLOGICAL:** Ad26.RSV.FA2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02440035
- **Lead sponsor:** Crucell Holland BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-21
- **Primary completion:** 2016-06-09
- **Final completion:** 2016-06-09
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2017-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02440035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02440035, "A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02440035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*